Adalimumab for the treatment of pediatric Crohn’s disease

Nuti, Federica; Fiorino, Gionata; Danese, Silvio

doi:10.1586/1744666x.2015.1072048

Cited by 6 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNFα is an inflammatory cytokine produced by macrophages/monocytes during acute inflammation such as seen with autoimmune disorders (Willrich et al, 2015). Adalimumab is a monoclonal antibody that inactivates TNFα thus reducing its inflammatory effects (Nuti et al, 2015;Willrich et al, 2015) and sold under the brand name Humira ® (AbbVie, Lake Bluff, Illinois, United States), among others (Scheinfeld, 2003;Coghlan et al, 2021). This monoclonal antibody has been used to treat a variety of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and uveitis, among others.…”

Section: Discussionmentioning

confidence: 99%

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Yamaguchi

Dam²,

Dhalla³

et al. 2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

Biotherapeutics such as peptides and antibodies are highly efficacious clinically but, unlike conventional medications, cannot be administered orally as they get digested and inactivated. Thus, biotherapeutics require parenteral routes for delivery, such as intravenous, intramuscular or subcutaneous administration. However, these delivery methods have limitations such as poor patient compliance or may require clinical supervision compared to oral therapies. We explored whether a novel, orally administered transenteric delivery system (Robotic Pill) could provide equivalent bioavailability to parenterally administered drugs. Utilizing an awake canine model, we demonstrated that orally administered Robotic Pills containing either human IgG or an anti-cytokine monoclonal antibody directed against either TNFα or interleukin-17A yielded bioavailability equivalent to parenterally administered controls. The ability to achieve clinically relevant blood levels of biotherapeutics via any orally administered preparation represents an important advance in drug delivery.

show abstract

Section: Discussionmentioning

confidence: 99%

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Yamaguchi

Dam²,

Dhalla³

et al. 2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

show abstract

“…It modulates downstream processes mobilized or regulated by TNF-α by blocking its interaction with p75 and p55 cell surface TNF receptors after binding to TNF-α [ 140 ]. Adalimumab has been used in autoimmune diseases, such as psoriasis, Crohn's disease, and noninfectious uveitis [ 141 – 143 ]. Although not widely used, adalimumab has been reported in adults and children to treat OIP, which can relieve symptoms and reduce the dose of glucocorticoids.…”

Section: Treatmentmentioning

confidence: 99%

Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

Fang,

Shen,

Dai

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Orbital inflammatory pseudotumor (OIP) is a benign, non-specific inflammatory disorder that commonly occurs in middle-aged adults and is usually unilateral but can occur bilaterally. Its clinical manifestations have tremendous clinical heterogeneity and vary according to the site of infiltration and the degree of lesions, including orbital pain, swelling, diplopia, proptosis, restricted eye movement, and decreased visual acuity. Clinical features, Image characteristics and pathological examinations often need to be evaluated to confirm the diagnosis. Currently, there is no systematic research on the pathogenesis of OIP, which may be related to immunity or infection. The first-line treatment is glucocorticoids. Radiotherapy, immunosuppressants, and biologics can be considered for treatment-resistant, hormone-dependent, or intolerant patients. In this review, we aim to summarize and focus on new insights into OIP, including new diagnostic criteria, pathogenesis, and discoveries in new drugs and treatment strategies. In particular, we highlight the literature and find that T cell-mediated immune responses are closely related to the pathogenesis of OIP. Further exploration of the mechanism and signaling pathway of T cells in the immune process will help to identify their therapeutic targets and carry out targeted therapy to treat refractory OIP and reduce the side effects of traditional treatments.

show abstract

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Navas-López

Pujol-Muncunill

Llerena

et al. 2018

Anales de Pediatría (English Edition)

View full text Add to dashboard Cite

Adalimumab for the treatment of pediatric Crohn’s disease

Cited by 6 publications

References 73 publications

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Contact Info

Product

Resources

About